El interés en corto de Edesa Biotech da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Edesa Biotech. Los datos de interés en corto se actualizan cada dos semanas.

Edesa Biotech (NASDAQ:EDSA) Bolsa, Informe de interés en corto

Edesa Biotech

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AMOD

DGLY

EDSA

El Índice de Precios al Productor en EE. UU. subió un 3,5% en enero, superando las previsiones. ¿Cómo reaccionaron los mercados?

Acciones de EE. UU. reaccionan al alza tras el aumento del PPI: ¿qué esperar ahora?

Edesa Biotech Inc

WIIM

CYCU

Cycurion shares are trading higher after the company announced an expanded partnership with Journal Technologies and a $22 million multi-year contract with a state police agency.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/07/final-trades-berkshire-hathaway-first-citizens-bancshares-and-kla-corp.html">Halftime Report Final Trades</a>,&#8221; Brian Belski of BMO Capital Markets named First Citizens Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) as his <a href="https://www.benzinga.com/quote/FCNCA/earnings">final trade</a>.
On the earnings front, First Citizens will report its financial results for the quarter ended March 31, before the opening bell on Thursday, April 24. 
Analysts expect the firm to report quarterly earnings at $37.87 per share, down from $52.92 per share in the year-ago period. The company projects quarterly revenue of $2.22 billion, compared to $2.29 billion a year earlier.
Jim Lebenthal of Cerity Partners picked Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>).
The Wall Street Journal reported last month that Compass was in talks to buy Warren Buffett&#8216;s <a href="https://www.benzinga.com/ma/25/03/44317138/warren-buffetts-real-estate-brokerage-compass-discuss-deal-report">real estate brokerage unit</a>.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
Jason Snipe of Odyssey Capital Advisors named KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>).
Morgan Stanley analyst Shane Brett supported his view on March 31, upgrading KLA&#8217;s rating from Equal-Weight to Overweight and raising the price target from $748 to $870.
Price Action:
<ul>
<li>First Citizens BancShares shares gained 2.2% to close at $1,606.17 on Monday.</li>
<li>Berkshire Hathaway shares fell 0.6% to close at $490.38 during Monday's session.</li>
<li>KLA shares gained 4.9% to settle at $604.62 on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a></li>
</ul>
Image: Shutterstock

Media

FCNCA

KLAC

First Citizens Bancshares, Berkshire Hathaway And A Tech Stock On CNBC's 'Final Trades'

William Blair analyst Lachlan Brown initiates coverage on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Outperform rating.

Initiation

Analyst Ratings

OCUL

William Blair Initiates Coverage On Ocular Therapeutix with Outperform Rating

Biotech

General

RLYB

Rallybio to Discontinue Development Of RLYB212 In Prevention Of FNAIT, Says RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy

<a href="https://www.wsj.com/business/deals/janus-henderson-strikes-deal-to-manage-45-billion-of-insurers-assets-4de6b4de" title="https://www.wsj.com/business/deals/janus-henderson-strikes-deal-to-manage-45-billion-of-insurers-assets-4de6b4de">https://www.wsj.com/business/deals/janus-henderson-strikes-deal-to-manage-45-billion-of-insurers-assets-4de6b4de</a>

Contracts

Janus Henderson Group plc Ordinary Shares

Janus Enters Partnership With Guardian Life To Manage $45B And Develop New Products, Executives Say

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) with a Buy and maintains $4.25 price target.

Price Target

Reiteration

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Opus Genetics Announces One-Month Clinical Data From Pediatric Patient in Phase 1/2 Trial; Says First Pediatric Patient Shows Encouraging Early Safety Profile And Meaningful Improvement In Visual Function At One Month

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy and maintains $28 price target.

KALV

Needham Reiterates Buy on KalVista Pharma, Maintains $28 Price Target

Citigroup analyst Ariel Rosa upgrades Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) from Sell to Neutral and lowers the price target from $32 to $29.

Upgrades

WERN

Citigroup Upgrades Werner Enterprises to Neutral, Lowers Price Target to $29

Health Care

ADPT

Adaptive Biotechnologies Announces That Palmetto GBA, A Medicare Administrative Contractor Expanded Coverage Of clonoSEQ

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/DAL/earnings">opening bell on Wednesday, April 9</a>.
Analysts expect the company to report quarterly earnings at 39 cents per share, down from 45 cents per share in the year-ago period. Delta Air Lines projects quarterly revenue of $13.46 billion, compared to $13.75 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Monday, UBS analyst Thomas Wadewitz downgraded Delta from Buy to Neutral. He also lowered the price target from $77 to $42. Susquehanna analyst Christopher Stathoulopoulos maintained the stock with a Positive rating and slashed the price target from $80 to $50.
With the recent buzz around Delta Air Lines, some investors may be eyeing potential gains from the company's dividends too. As of now, Delta Air Lines offers an annual dividend yield of 1.61%. That&#8217;s a quarterly dividend amount of 15 cents per share (60 cents a year).
To figure out how to earn $500 monthly from Delta Air Lines, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Delta's $0.60 dividend: $6,000 / $0.60 = 10,000 shares.
So, an investor would need to own approximately $372,900 worth of Delta Air Lines, or 10,000 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.60 = 2,000 shares, or $74,580 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
DAL Price Action: Shares of Delta Air Lines gained by 0.1% to close at $37.29 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a></li>
<li>Image: Shutterstock</li>
</ul>

Long Ideas

How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q1 Earnings

Citigroup analyst Ariel Rosa upgrades Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Neutral to Buy and lowers the price target from $260 to $244.

Citigroup Upgrades Union Pacific to Buy, Lowers Price Target to $244

SCNX

SCIENTURE Announces Divestiture Of Its Legacy Healthcare IT And Wholesale Operations Subsidiaries To Tollo Health

Micron Tells U.S. Customers It Will Impose A Tariff-Related Surcharge On Some Products From April 9, 2025

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL&#x2122;
JOTROL&#x2122; development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure
Jupiter, Florida, April 08, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL&#x2122;, a patented resveratrol-based platform, today announced the release of its first shareholder letter as a publicly traded company. The letter from Chairman and CEO Christer Rosén outlines the Company's 2025 strategic roadmap, including key clinical and commercial milestones designed to create long-term value and establish near-term revenue.
Dear Fellow Shareholders,
It is a distinct pleasure to share our first annual letter to shareholders, following our successful debut on the Nasdaq Capital Market in December 2024 under the symbol JUNS. That significant milestone marked more than just an entry into the public markets — it signaled the beginning of a new era for Jupiter Neurosciences, defined by increased visibility, enhanced resources, and a bold vision for advancing transformative therapies in neuroscience and longevity.
Building Momentum
With our Nasdaq listing in place, we are now focused on advancing our lead clinical asset, JOTROL&#x2122;, into a Phase 2a clinical trial in Parkinson's disease, expanding our presence in Asia, and launching a new consumer-facing longevity initiative. Becoming a publicly traded company has amplified awareness of our mission — to pioneer treatments that target the underlying causes of neuroinflammation and mitochondria in both rare and widespread neurological disorders. By entering the rapidly growing Longevity and Healthspan market, we are leveraging years of preclinical and clinical development with JOTROL&#x2122; to establish a scientifically grounded, near-term revenue-generating business alongside our therapeutic pipeline.
JOTROL&#x2122;: Unlocking Resveratrol's Untapped Potential
At the core of our pipeline is JOTROL&#x2122;, an enhanced resveratrol formulation developed in partnership with Aquanova AG. Leveraging proprietary micellar technology, JOTROL&#x2122; resolves long-standing bioavailability and gastrointestinal tolerability issues that have hindered therapeutic resveratrol applications for decades. Our Phase 1 study demonstrated more than nine-fold improved bioavailability versus standard resveratrol, and this data now serves as the regulatory foundation across all upcoming clinical trials.
With its ability to cross the blood-brain barrier and modulate key inflammatory pathways such as NLRP3, JOTROL&#x2122; is uniquely positioned as a novel therapeutic platform for neurodegenerative diseases, including Parkinson's disease (JNS115) and Mild Cognitive Impairment/Early Alzheimer's (JNS108). The additional benefit of JOTROL&#x2122; increasing mitochondrial structure and function is a compounding mechanism that is core to our therapeutic strategy, with treatment benefit in neurodegenerative disease and cancer. Our upcoming Parkinson's trial, in collaboration with Zina Biopharmaceuticals and Catalent, is on track to begin dosing in Q3 2025.

JUNS

Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter Including Lead Clinical Asset, Jotrol Into A Phase 2A Clinical Trial In Parkinson's Disease

Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and maintains $15 price target.

Needham Reiterates Buy on Ocular Therapeutix, Maintains $15 Price Target

AMTX

Aemetis Production Of Renewable Natural Gas Increased 55% In Mar.

Management

NNDM

Nano Dimension Appoints Ofir Baharav As CEO

Citigroup analyst Ariel Rosa upgrades Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) from Sell to Neutral and lowers the price target from $25 to $23.

SNDR

Citigroup Upgrades Schneider National to Neutral, Lowers Price Target to $23

<ul>
<li>Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1</li>
<li>Long-term seizure reduction with a median reduction of 82% at 3 years.</li>
<li>Seizure freedom with 42% of patients remaining seizure free for 6+ months.i</li>
</ul>

NPCE

NeuroPace Presented Data From Long-Term Post-Approval Study Of RNS System On Apr. 7; Says Long-Term Seizure Reduction With A Median Reduction Of 82% At 3 Years

Events

Press Releases

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Edesa Biotech Announces Upcoming Conference Schedule

Financing

Edesa Biotech's Founder Makes Strategic Investment in the Company

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces Chief Financial Officer Transition

HC Wainwright & Co.

Brookline Capital

Comments

Edesa Biotech

Interés en corto

Edesa Biotech (NASDAQ:EDSA) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL